DDInter504 DDInter1899
Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use
Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than 80%. Maintenance of the airway is controlled by the parasympathetic nervous system, particularly by the abundance of the muscarinic subtype 3 (M3) in the airway smooth muscle. Parasympathetic ganglia are associated with the larger airways while postganglionic fibers innervate the smaller diameter bronchioles contributing to airway resistance. By blocking the M3 muscarinic receptor, umeclidinium inhibits the binding of acetylcholine and thereby opens up the airways by preventing bronchoconstriction. However, even though umeclidinium monotherapy is well-tolerated for up to 14 days, it is more likely to be used in combination therapy, as the international Gold Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommended the use of two long-acting bronchodilators with differing mechanisms of action to maximize efficacy and minimize adverse effects.[A7718,A7714] Umeclidinium was approved by the FDA in April 2014 under the brand name Incruse Ellipta as a standalone product. Later, it was further approved as a combination product with [vilanterol] and [vilanterol]/[fluticasone furoate] under the brand name ANORO ELLIPTA and TRELEGY ELLIPTA respectively.[L44461,L44456]. ANORO ELLIPTA was approved in December 2013 while TRELEGY ELLIPTA was approved in September 2017.[L46881,L46886]
Desipramine {u} (Compound) resembles {v} (Compound) Promethazine
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Umeclidinium
Desipramine {u} (Compound) resembles {v} (Compound) Protriptyline
Protriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Umeclidinium
Desipramine {u} (Compound) resembles {v} (Compound) Promethazine
Promethazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepyramine
Mepyramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Umeclidinium
Desipramine {u} (Compound) resembles {v} (Compound) Protriptyline
Protriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepyramine
Mepyramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Umeclidinium
Desipramine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Mepyramine
Mepyramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Umeclidinium
Desipramine {u} (Compound) resembles {v} (Compound) Promethazine
Promethazine {u} may lead to a major life threatening interaction when taken with {v} Haloperidol
Haloperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Umeclidinium
Desipramine {u} (Compound) resembles {v} (Compound) Azatadine
Azatadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Haloperidol
Haloperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Umeclidinium
Desipramine {u} (Compound) resembles {v} (Compound) Promazine
Promazine {u} (Compound) resembles {v} (Compound) Orphenadrine
Orphenadrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Umeclidinium
Desipramine {u} (Compound) resembles {v} (Compound) Promethazine
Promethazine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orphenadrine
Orphenadrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Umeclidinium
Desipramine {u} (Compound) resembles {v} (Compound) Azatadine
Azatadine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Loxapine
Loxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Umeclidinium
Desipramine (Compound) resembles Promethazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Desipramine (Compound) resembles Protriptyline (Compound) and Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Desipramine (Compound) resembles Promethazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Desipramine (Compound) resembles Protriptyline (Compound) and Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Desipramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound) and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Desipramine (Compound) resembles Promethazine (Compound) and Promethazine may lead to a major life threatening interaction when taken with Haloperidol and Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Desipramine (Compound) resembles Azatadine (Compound) and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Haloperidol and Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Desipramine (Compound) resembles Promazine (Compound) and Promazine (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Desipramine (Compound) resembles Promethazine (Compound) and Promethazine (Compound) resembles Orphenadrine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Desipramine (Compound) resembles Azatadine (Compound) and Azatadine (Compound) resembles Loxapine (Compound) and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Loxapine and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium